NCT01460407

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Effect of Clarithromycin on the Pharmacokinetics of LY2216684 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The study will evaluate the effect of Clarithromycin on the pharmacokinetics (PK) of LY2216684 in healthy participants. Side effects will be documented. There will be 2 study periods (5 and 9 days) and follow up will occur at least 7 days after the last dose. Screening is required within 45 days prior to the start of the study.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	LY2216684	Administered orally
DRUG	Clarithromycin	Administered orally

Timeline

• Start date: 2011-10-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-10-26
• Last updated: 2018-10-19
• Results posted: 2018-10-19

Locations

1 site across 1 country: United States